BTG (LON:BTG)‘s stock had its “hold” rating reissued by Peel Hunt in a research note issued on Tuesday.

Several other research analysts have also commented on BTG. JPMorgan Chase dropped their price objective on shares of BTG from GBX 750 ($10.17) to GBX 680 ($9.22) and set a “neutral” rating for the company in a research note on Friday, April 6th. Numis Securities reaffirmed a “buy” rating and set a GBX 900 ($12.21) price objective on shares of BTG in a research note on Wednesday, January 24th. Finally, Shore Capital raised shares of BTG to a “buy” rating in a research note on Monday, March 26th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. BTG currently has a consensus rating of “Buy” and an average price target of GBX 779.71 ($10.58).

Shares of BTG opened at GBX 632.95 ($8.59) on Tuesday. BTG has a fifty-two week low of GBX 559.82 ($7.59) and a fifty-two week high of GBX 784 ($10.63).

BTG (LON:BTG) last posted its quarterly earnings data on Tuesday, May 15th. The company reported GBX 32.90 ($0.45) EPS for the quarter, topping the consensus estimate of GBX 29.80 ($0.40) by GBX 3.10 ($0.04). BTG had a net margin of 15.50% and a return on equity of 10.80%.

BTG Company Profile

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with's FREE daily email newsletter.